A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Period, Cross-Over Single Day Evaluation Of The Pharmacokinetic-Pharmacodynamic Effect Of Once And Twice Daily Oral Administration Of PF-04971729 In Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase I
Latest Information Update: 25 May 2016
At a glance
- Drugs Ertugliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 23 Apr 2010 Actual end date (April 2010) added as reported by ClinicalTrials.gov.
- 23 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.